BioMed Ventures is the strategic venture investment arm of BioMed Realty Trust, Inc., a life science-focused real estate investment trust. Founded in 2010 and based in San Diego, it invests in early- to growth-stage life sciences and biotechnology companies aligned with the parent REIT's ecosystem.
43% of their portfolio is in Biotech & Life Sciences. They made 1 investment in the last 12 months. Average disclosed round size is $42.2M (across 20 rounds with reported amounts).
Portfolio
19
Fund Size
—
Top Stage
Series C
Last 12 Mo
1
Team
BS
Bruce Steel
Founder and managing director
SC
Stephen Connelly
Principal
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
28 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| PPrecirix | Series B | — | Aug 2026 |
 ImmunOs Therapeutics | Series C | $11M | Sep 2024 |
 ImmunOs | Series C | $11M | Sep 2024 |
 TRiCares | Series C | $55M | Dec 2022 |
| TRiCares | Series C | — | Sep 2022 |
| ImmunOs Therapeutics | Series B | $74M | Jun 2022 |
| ImmunOs | Series B | $74M | Jun 2022 |
| PPrecirix | Series B | — | Mar 2022 |
| PPrecirix | Seed | — | Jan 2022 |
 Fauna Bio | Seed | $9M | Sep 2021 |
| FFauna | Unknown | $9M | Sep 2021 |
 Alentis Therapeutics | Series B | — | Jun 2021 |
| AAlentis | Series B | — | Jan 2021 |
| Alentis Therapeutics | Series B | $67M | Jan 2021 |
 Noema Pharma | Series A | — | Dec 2020 |
 Amplyx Pharmaceuticals, Inc. | Series C | — | May 2020 |
| AAegea | Series C | $40M | Jan 2018 |
| Amplyx Pharmaceuticals, Inc. | Series C | $67M | Aug 2017 |
 Effector Therapeutics | Series C | $38.6M | Jul 2017 |
| NNeuroVia, Inc. | Series A | $14M | Jul 2017 |
| Effector Therapeutics | Series B | $40M | Dec 2015 |
 Amplyx | Series B | $40.5M | Nov 2015 |
 AnaptysBio | Unknown | $86.3M | Sep 2015 |
 Syndax Pharmaceuticals | Series C | $80M | Aug 2015 |
 Syndax | Series C | $80M | Jan 2015 |
Page 1 of 2
Top Co-Investors
Gimv7 shared
Jeito Capital6 shared
Pfizer Ventures6 shared
Mission BioCapital5 shared
Cormorant Asset Management5 shared
Sofinnova Partners4 shared
Lightspeed Venture Partners4 shared
Pontifax3 shared
Forbion3 shared
HealthCap3 shared
Novo Holdings A/S3 shared
INKEF Capital3 shared
Schroders Capital3 shared
Morningside3 shared
High-Tech Gründerfonds3 shared
Novo Capital3 shared
New Enterprise Associates3 shared
RiverVest Venture Partners3 shared
Pappas Capital3 shared
U.S. Venture Partners2 shared
Last updated: 20 October 2026